Patently Obvious Update from TechDirt: “Those Ex-Theranos Patents Look Really Bad; Contest Opened To Find Prior Art To Get Them Invalidated”
Mike Masnick
A few weeks back we wrote about how Fortress Investment Group — a massive patent trolling operation funded by Softbank — was using old Theranos patents to shake down BioFire, a company that actually makes medical diagnostics tests, including one for COVID-19. Fortress had scooped up the patents as collateral after it issued a loan to Theranos, which Theranos (a complete scam company, whose founders are still facing fraud charges…) could not repay. Fortress then set up a shell company, Labrador Diagnostics, which did not exist until days before it sued BioFire. After it (and the law firm Irell & Manella) got a ton of bad press for suing BioFire over these patents — including the COVID-19 test — Fortress rushed out a press release promising that it would issue royalty-free licenses for COVID-19 tests. However, it has still refused to reveal the terms of that offer, nor has it shared the letter it sent to BioFire with that offer.
And while some have argued that after issuing this “royalty-free license” offer, the whole thing was now a non-story, that’s not true. It appears that the offer only covers half of the test: the pouches that have the test-specific reagents, but not the test device that is used to analyze the tests. And so while the COVID-19 test pouches may get a “free” license, the machines to test them are still subject to this lawsuit.
If you’re looking to help out and would like a place to start, the good folks at M-CAM, who analyze patents for prior art and obviousness, have a fairly remarkable analysis of the Theranos patents, and refers to Fortress/Softbank/Labrador as “graverobbers.” The analysis is worth reading, including this analysis of the 1st claim in the patent for “a two-way communication system for detecting an analyte in a bodily fluid from a subject…”:
Sorry, the comment form is closed at this time.